EGFR and lung adenocarcinoma: In addition, we detected the synergistic effect of gefitinib and BYL719 in organoids derived from a lung adenocarcinoma patient, harboring EGFR (L838V, L861Q), PIK3CA (H1047L), ErbB2 (D871N) mutations and MET amplification.